- $668.57m
- $713.43m
- $7.50m
- 24
- 32
- 90
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.31 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 89.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.59% | ||
| Return on Equity | -14.49% | ||
| Operating Margin | -735.47% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 16.72 | 32.16 | 7.46 | 10.21 | 7.5 | 7.29 | 9.51 | -15.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Directors
- Joseph Swedish NEC (69)
- Silviu Itescu CEO
- William Burns VCH (73)
- Andrew Chaponnel CFO
- Dagmar Rosa - Bjorkeson COO (57)
- Peter Howard GCN
- Justin Horst OTH
- Michael Schuster OTH
- Paul Simmons OTH
- Geraldine Storton OTH
- Eric Rose NED (70)
- Philip Facchina NID (57)
- Donal O'Dwyer NID (68)
- Michael Spooner NID
- Shawn Tomasello NID (62)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 8th, 2004
- Public Since
- December 16th, 2004
- No. of Shareholders
- 34,816
- No. of Employees
- 83
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 1,014,799,334
- Address
- L 38 55 Collins St, MELBOURNE, 3000
- Web
- https://www.mesoblast.com/
- Phone
- +61 396396036
- Auditors
- PricewaterhouseCoopers
Upcoming Events for MESO
Similar to MESO
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 22:02 UTC, shares in Mesoblast are trading at $6.56. This share price information is delayed by 15 minutes.
Shares in Mesoblast last closed at $6.56 and the price had moved by +100% over the past 365 days. In terms of relative price strength the Mesoblast share price has outperformed the S&P500 Index by +56.38% over the past year.
The overall consensus recommendation for Mesoblast is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMesoblast does not currently pay a dividend.
Mesoblast does not currently pay a dividend.
Mesoblast does not currently pay a dividend.
To buy shares in Mesoblast you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.56, shares in Mesoblast had a market capitalisation of $668.57m.
Here are the trading details for Mesoblast:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MESO
Based on an overall assessment of its quality, value and momentum Mesoblast is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mesoblast is $11.00. That is 67.68% above the last closing price of $6.56.
Analysts covering Mesoblast currently have a consensus Earnings Per Share (EPS) forecast of -$0.72 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mesoblast. Over the past six months, its share price has outperformed the S&P500 Index by +182.4%.
As of the last closing price of $6.56, shares in Mesoblast were trading +43.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mesoblast PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mesoblast's management team is headed by:
- Joseph Swedish - NEC
- Silviu Itescu - CEO
- William Burns - VCH
- Andrew Chaponnel - CFO
- Dagmar Rosa - Bjorkeson - COO
- Peter Howard - GCN
- Justin Horst - OTH
- Michael Schuster - OTH
- Paul Simmons - OTH
- Geraldine Storton - OTH
- Eric Rose - NED
- Philip Facchina - NID
- Donal O'Dwyer - NID
- Michael Spooner - NID
- Shawn Tomasello - NID